Abstract
The heptad repeats (HR1 and HR2) of the spike protein of SARS-CoV are highly conserved regions forming a critical 6-helix bundle during the fusion step of virus entry and are attractive targets of entry inhibitors. In this study, we report that a minimal HR2 peptide, P6 of 23-mer, can block the fusion of SARS-CoV with an IC(50) of 1.04+/-0.22 microM. This finding supports the structural prediction of the deep groove of HR1 trimer as a target for fusion inhibitors, and suggests P6 as a potential lead peptide for future drug development. Moreover, combination of an HR-1 peptide, N46, and its mutated version, N46eg, shows synergistic inhibition with an IC(50) of 1.39+/-0.05 microM and combination index of 0.75+/-0.15, suggesting a common strategy to achieve promising inhibition by HR1 peptide for other class I envelope viruses.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Chlorocebus aethiops
-
Humans
-
Membrane Glycoproteins / chemistry*
-
Membrane Glycoproteins / genetics
-
Membrane Glycoproteins / metabolism
-
Membrane Glycoproteins / pharmacology
-
Molecular Sequence Data
-
Peptides / chemistry
-
Peptides / pharmacology*
-
Protein Structure, Secondary
-
Sequence Alignment
-
Severe Acute Respiratory Syndrome / drug therapy*
-
Severe Acute Respiratory Syndrome / virology
-
Severe acute respiratory syndrome-related coronavirus / chemistry*
-
Severe acute respiratory syndrome-related coronavirus / drug effects*
-
Severe acute respiratory syndrome-related coronavirus / genetics
-
Severe acute respiratory syndrome-related coronavirus / metabolism
-
Spike Glycoprotein, Coronavirus
-
Vero Cells
-
Viral Envelope Proteins / chemistry*
-
Viral Envelope Proteins / genetics
-
Viral Envelope Proteins / metabolism
-
Viral Envelope Proteins / pharmacology
-
Virus Internalization / drug effects*
Substances
-
Membrane Glycoproteins
-
Peptides
-
Spike Glycoprotein, Coronavirus
-
Viral Envelope Proteins